)
)
Celcuity Investor Relations Material
Latest events
Q3 2024
Celcuity
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Celcuity Inc
Access all reports
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company develops Tarcelisib, a small molecule inhibitor of protein kinase ribosomal S6 kinase beta (S6K1) for the treatment of solid tumors. Its clinical programs include Phase II Soliloquy study for rTRT in hormone refractory prostate cancer and Phase I Celcuity 9088 study investigating Tarcelisib as a treatment for endometrial cancer.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
CELC
Country
🇺🇸 United States